This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
Retraction: Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHistone Deacetylase Inhibitors Research · Protein Degradation and Inhibitors · Peptidase Inhibition and Analysis
After this article [1] was published, concerns were raised regarding results presented in Figs 2, 3, 5 and 6. Specifically,
The authors did not respond to the editorial request for comment on these concerns.
In light of the above concerns, which call into question the integrity and reliability of [1], the PLOS One Editors retract this article.
All authors either did not respond directly or could not be reached.
The reference list from the paper itself. Each links out to its DOI / PubMed record.